Lecanemab (Leqembi®) is approved in the United States for the treatment of Alzheimer's
disease (AD) to be initiated in early AD (mild cognitive impairment [MCI] due to AD or mild …

The shared role of amyloid-β (Aβ) deposition in cerebral amyloid angiopathy (CAA) and
Alzheimer disease (AD) is arguably the clearest instance of crosstalk between …

Background Cerebral amyloid angiopathy (CAA) is an age-related small vessel disease,
characterised pathologically by progressive deposition of amyloid β in the cerebrovascular …

Expanding the US Food and Drug Administration–approved indications for immune
checkpoint inhibitors in patients with cancer has resulted in therapeutic success and …

492 Stroke February 2018 lobar hemorrhages required for probable CAA, or alternatively
preclude probable CAA if in deep territories. The rationale for counting all types of …

We report the case of a 79-year-old woman with Alzheimer's disease who participated in a
Phase III randomized controlled trial called CLARITY-AD testing the experimental drug …

Sporadic cerebral amyloid angiopathy is a common, well-defined small vessel disease and
a largely untreatable cause of intracerebral haemorrhage and contributor to age-related …

SVD is the leading cause of VCI and is associated with substantial morbidity. Tackling
cardiovascular risk factors is currently the most effective approach to prevent cognitive …

Background and Objectives The goal of this work was to investigate the natural history and
outcomes after treatment for spontaneous amyloid-related imaging abnormalities (ARIA)-like …

Cerebrovascular disease underpins vascular dementia (VaD), but structural and functional
changes to the cerebral vasculature contribute to disease pathology and cognitive decline in …